Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: Lessons learned from a health care services study

BackgroundRecent guidelines recommend assessment and treatment of the overall risk for cardiovascular disease (CVD) through management of multiple risk factors in patients at high absolute risk. The aim of our study was to assess the level of cardiovascular risk in patients with known risk factors for CVD by applying the SCORE risk function and to study the implications of European guidelines on the use of treatment and goal attainment for blood pressure (BP) and lipids in the primary care of Cyprus.MethodsRetrospective chart review of 1101 randomly selected patients with type 2 diabetes mellitus (DM2), or hypertension or hyperlipidemia in four primary care health centres. The SCORE risk function for high-risk regions was used to calculate 10-year risk of cardiovascular fatal event. Most recent values of BP and lipids were used to assess goal attainment to international standards. Most updated medications lists were used to compare proportions of current with recommended antihypertensive and lipid-lowering drug (LLD) users according to European guidelines.ResultsImplementation of the SCORE risk model labelled overall 39.7% (53.6% of men, 31.3% of women) of the study population as high risk individuals (CVD, DM2 or SCORE ≥5%). The SCORE risk chart was not applicable in 563 patients (51.1%) due to missing data in the patient records, mostly on smoking habits. The LDL-C goal was achieved in 28.6%, 19.5% and 20.9% of patients with established CVD, DM2 (no CVD) and SCORE ≥5%, respectively. BP targets were achieved in 55.4%, 5.6% and 41.9% respectively for the above groups. There was under prescription of antihypertensive drugs, LLD and aspirin for all three high risk groups.ConclusionThis study demonstrated suboptimal control and under-treatment of patients with cardiovascular risk factors in the primary care in Cyprus. Improvement of documentation of clinical information in the medical records as well as GPs training for implementation and adherence to clinical practice guidelines are potential areas for further discussion and research.

[1]  D. Wood,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.

[2]  A. Eggen,et al.  Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromsø study 2001 , 2004, European Journal of Clinical Pharmacology.

[3]  D. Atar,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[4]  A. Eggen,et al.  Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. , 2005, European heart journal.

[5]  J Marrugat,et al.  An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas , 2003, Journal of epidemiology and community health.

[6]  I. Graham.  Guidelines on cardiovascular disease prevention in clinical practice: the European perspective , 2005, Current opinion in cardiology.

[7]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[8]  H. von Gizycki,et al.  Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. , 2002, Diabetes care.

[9]  M. Stewart,et al.  The role of patient, physician and systemic factors in the management of type 2 diabetes mellitus. , 2002, Family practice.

[10]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[11]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[12]  Michael L. Johnson,et al.  Therapeutic Goal Attainment in Patients With Hypertension and Dyslipidemia , 2006, Medical care.

[13]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[14]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[15]  G. W. Ward.  The National High Blood Pressure Education Program , 1984 .

[16]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[17]  Assessment of Hypercholesterolemia Control in a Managed Care Organization , 2001, Pharmacotherapy.

[18]  C. Brotons,et al.  Consequences of using different methods to assess cardiovascular risk in primary care. , 2006, Family practice.

[19]  Helmut Schulte,et al.  Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. , 2003, European heart journal.

[20]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[21]  M. Boemi,et al.  The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy. , 2008, Atherosclerosis.

[22]  R. Hanson,et al.  The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. , 2000, Diabetes care.

[23]  P E Puddu,et al.  Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. , 2000, European heart journal.

[24]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[25]  J. Librero,et al.  Auditing secondary prevention of ischaemic heart disease in rural areas of Spain: An opportunity for improvement , 2006, The European journal of general practice.

[26]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[27]  D. Simon,et al.  Management of diabetic patients by general practitioners in France 1997: an epidemiological study. , 2000, Diabetes & metabolism.

[28]  C. Lenfant,et al.  National High Blood Pressure Education Program. , 1986, Journal of the American Optometric Association.

[29]  L. Getz,et al.  Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study , 2005, BMJ : British Medical Journal.

[30]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[31]  J. Straand,et al.  Which population groups should be targeted for cardiovascular prevention? A modelling study based on the Norwegian Hordaland Health Study (HUSK) , 2007, Scandinavian journal of primary health care.